Trial reportDrugs & aging2003
Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE).
Trial report in Drugs & aging, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017Guideline
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.Lancet (London, England) · 2009 · on this mapPooled it
- Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.The New England journal of medicine · 2018Trial
- Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial.Contemporary clinical trials · 2013Trial
- Association between migraine and the risk of vascular dementia: A nationwide longitudinal study in South Korea.PloS one · 2024Article
- Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.Annals of family medicine · 2017Article
- Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events.Journal of thrombosis and thrombolysis · 2016Review
- The role of aspirin in the prevention of cardiovascular disease.Clinical medicine & research · 2014Review
- Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled.World journal of gastroenterology · 2014Review
- Vascular cognitive impairment and post-stroke cognitive deficits.Current neurology and neuroscience reports · 2014Review
- Small vessel disease and memory loss: what the clinician needs to know to preserve patients' brain health.Current cardiology reports · 2013Review
- Role of aspirin in cancer prevention.Current oncology reports · 2013Review
- Understanding and treating vascular cognitive impairment.Continuum (Minneapolis, Minn.) · 2013Review
- Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.Circulation research · 2013Article
- Aspirin for primary prevention of cardiovascular events in the elderly: current status and future directions.Drugs & aging · 2012Review
- Prevention. Aspirin in primary prevention--good news and bad news.Nature reviews. Cardiology · 2012Article
- Review
- Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions.Current atherosclerosis reports · 2007Review
- Diagnosis and management of vascular cognitive impairment.Current atherosclerosis reports · 2007Review
- Neuropsychiatric consequences of cardiovascular medications.Dialogues in clinical neuroscience · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-dose aspirin (acetylsalicylic acid) therapy has been shown to reduce the risk of vascular events and there is increasing evidence of its potential to reduce the rate of cognitive decline in the elderly. Adverse effects including gastrointestinal and intracranial haemorrhage may offset these benefits. The balance of risks versus benefits of aspirin for the primary prevention of cardiovascular disease and vascular dementia has not been established in the elderly. There is clearly a need to conduct a study in family practice to investigate whether routine use of low-dose aspirin for the primary prevention of cardiovascular disease and vascular dementia in the elderly is beneficial or harmful. Aspirin in reducing events in the elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia. It will follow 15,000 subjects aged 70 years or more for an average of 5 years. This sample size has a power of 87% to detect a 15% reduction in primary events in the aspirin group, with an anticipated combined primary event rate of 20 per 1000 patient years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.